Source: Annual Congress 2006 - Community-acquired pneumonia: risk factors and treatment
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. L. Andreu Rodríguez, R. Blanquer Olivas, E. Fernández Fabrellas, F. Sanz, J. Blanquer Olivas, F. Tatay (Valencia, Spain). Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study. Eur Respir J 2006; 28: Suppl. 50, 2085

Member's Comments

No comment yet.

Related content which might interest you: Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP) Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 Determinants of performance of indicators on antibiotic use in community-acquired pneumonia (CAP) at hospitals Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Timing of previous hospitalizations impacts outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Ventilator-associated pneumonia, severe community-acquired pneumonia and healthcare associated pneumonia Year: 2009 Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study) Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Clinical factors associated with delayed diagnosis in hospitalized community-acquired pneumonia (CAP). Impact on the outcome Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia Year: 2010 Steroids are not associated with an improvement in clinical outcomes in hospitalized patients with community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment and prevention of lower respiratory tract infections Year: 2009 Clinical cure rates and infection types in the MOxifloxacin Treatment IV (MOTIV) study in hospitalized patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Intravenous steroids in the treatment of community-acquired pneumonia (CAP) Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004 Mortality directly related to community-acquired pneumonia (CAP) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Implementation of severity guided antibiotic treatment according to Dutch guidelines in hospitalized patients with community-acquired pneumonia (CAP) included in a clinical trial Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Optimizing treatment for community-acquired pneumonia in Denmark (The optiCAP study) Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Significant decrease in long-term survival for hospitalised patients with community-acquired pneumonia (CAP): results from the community-acquired pneumonia organisation (CAPO) international cohort study Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019